Add BrightSurf on Google Email

Scripps Research Institute


Structural studies offer “how-to” guide for designing cancer drugs

Researchers have discovered the three-dimensional structure of phosphoinositide 3-kinase alpha (PI3Kα) and how it changes with cancer-associated mutations. This knowledge enables the design of targeted drugs that can specifically bind to mutated versions, potentially eliminating side effects associated with current PI3Kα inhibitors.

SourceScripps Research Institute·JournalProceedings of the National Academy of Sciences·DateDec 9, 2022

Scripps Research chemists develop reactions for the general synthesis of promising unexplored compounds

Researchers at Scripps Research have developed a general synthesis method for 1,2,3,5-tetrazines, a family of compounds with great promise for making new pharmaceuticals and chemical products. The new method is more efficient than previous approaches, requiring just five reaction steps to produce myriad versions of these compounds.

SourceScripps Research Institute·JournalThe Journal of Organic Chemistry·DateDec 6, 2022

Drug discovery method identifies naturally occurring metabolite that converts ‘bad’ fat to ‘good’ fat

A team of scientists at Scripps Research and Calibr discovered a naturally occurring metabolite called myristoylglycine that can convert white fat cells into brown fat cells, potentially treating obesity and related diseases. The breakthrough uses a novel drug discovery method to identify endogenous metabolites with therapeutic potential.

SourceScripps Research Institute·JournalMetabolites·DateOct 13, 2022

Scripps Research scientists discover antibodies that induce broad immunity against SARS viruses, including emerging variants

Scientists at Scripps Research have identified antibodies that induce broad immunity against SARS viruses, including emerging variants. The discovery reveals the antibody structures that produce this more comprehensive immune response and could inform the development of next-generation vaccines.

SourceScripps Research Institute·JournalScience Translational Medicine·DateAug 10, 2022

Cellular protein identified as possible drug target to combat Lassa hemorrhagic fever

Researchers have identified 42 host cell proteins that contribute to the replication and spread of Lassa virus, a disease with high morbidity and mortality in Western Africa. One potential drug target, GSPT1, was found to be involved in viral-host interactions and showed antiviral activity against Lassa without cytotoxicity.

SourceScripps Research Institute·JournalProceedings of the National Academy of Sciences·DateJul 20, 2022